Introduction
Materials and methods
Literature search and study selection
Data extraction
Data analysis
Results
Literature search and study selection
Study | Technique | Designa
| No of patients analysed (m/f) | Patient spectrum (n) | Time interval between reference test and index test |
---|---|---|---|---|---|
Yajima 1983 | US | P | 45 (ND/ND) | 10 fatty liver; 8 chronic/acute hepatitis; 17 cirrhosis; 1 PSC; 9 other | ≤14 days |
Korte 1986 | US | P | 100 (67/33) | Suspected liver disease: alcohol abuse, diabetes, obesity | Mean 1.9 weeks |
Saverymuttu 1986 | US | P | 85 (ND/ND) | 50 ALD; 12 active hepatitis; 2 CPH; 3 PBC; 2 cryptogenic cirrhosis; 7 other; 4 normal | ≤28 days |
Lossner 1988 | US | P | 187 (ND/ND) | Suspected liver disease | Mean 11 days |
Joseph 1991 | US | P | 50 (ND/ND) | 30 ALD; 5 chronic persistent/reactive hepatitis; 4 cryptogenic cirrhosis; 2 PBC; 9 other | 0 days |
Caturelli 1992 | US | P | 35 (21/14) | Suspected liver disease | Unclear |
Hultcrantz 1993 | US | P | 83 (47/36) | 45 fatty liver; 14 cirrhosis; 11 chronic inflammation; 13 other | 0 days |
Dietrich 1998 | US | P | 68 (40/28) | HCV | Unclear |
Kutcher 1998 | US | R | 64 (39/25) | HCV | Unclear |
Graif 2000 | US | P | 28 (ND/ND) | 12 HCV; 1 HBV; 1 PBC; 3 non alcoholic cirrhosis; 11 other | ≤7 days |
Rinella 2001 | CT, MRI | R | 33 (19/14) | Potential living liver donors | Unclear |
Mathiesen 2002 | US | P | 165 (110/55) | 65 NAFLD; 25 HCV; 14 ALD; 3 NASH; 3 AIH; 2 PBC; 1 A-1-antitrypsin deficiency; 52 non-specific | 87% ≤ 28 days; |
Saadeh 2002 | US, CT, MRI | P | 25 (11/14) | 8 NAFLD; 17 NASH | ≤90 days |
Kichian 2003 | US | R | 49 (25/24) | NAFLD | Unclear |
Rinella 2003 | MRI | ND | 22 (13/9) | 15 potential living liver donors; 7 NAFLD | Unclear |
Iwasaki 2004 | CT | P | 266 (137/129) | Living liver donors | Unclear |
Limanond 2004 | CT | R | 42 (29/13) | Potential living liver donors | ≤28 days |
Hepburn 2005 | US | R | 164 (108/56) | HCV | Mean 1–2 months; range 0–6 months |
Kim SH 2005 | US | R | 94 (71/23) | Potential living liver donors | Mean 39.9 days; range 0–140 days |
Kim SH 2006 | MRI | R | 57 (40/17) | Potential living liver donors | Mean 14.5 days ± 18.8 days; range 0–124 d |
Palmentieri 2006 | US | P | 235 (127/108) | 146 HCV; 30 HBV; 3 HCV/HBV; 33 NAFLD; 23 other | Unclear |
Park 2006 | CT | P | 154 (104/50) | Potential living liver donors | 0 days |
Hamaguchi 2007 | US | P | 94 (ND/ND) | 68 NAFLD; 26 no disease | ≤30 days |
Hirche 2007 | US | P | 122 (78/44) | HCV | Unclear |
Lee JY 2007 | US, CT | R | 589 (408/181) | Potential living liver donors | Unclear |
Lee SW 2007 | CT | R | 48 (44/4)e
| Living liver donors | 0 days |
Perez 2007 | US | R | 131 (78/53) | 116 HCV; 5 HBV; 10 other | ≤9 months |
Bahl 2008 | MRI | P | 52 (15/37) | 29 NAFLD; 23 HCV/HIV | ≤4 months |
Chen 2008 | US | R | 108 (75/33) | 108 HCV | Unclear |
Cho 2008 | MRI, CT | R | 131 (66/65) | Liver resection for benign (5) or malignant disease (126) | Median 17 days |
Moura Almeida 2008 | US | P | 105 (26/79) | Bariatric surgery | Unclear |
Orlacchio 2008 | 1H-MRS | P | 30 (17/13) | HCV | ≤30 days |
Yoshimitsu 2008 | CT, MRI | R | 58 (35/23) | 38 potential living liver donors; 20 liver metastases | ≤14 days |
Crum-Cianflone 2009 | US | P | 216 (204/12) | HIV | Mean 5.2 months ± 3.6 months |
Dasarathy 2009 | US | P | 73 (48/25) | 38 HCV; 21 NAFLD; 7 HBV; 7 other | 0 days |
d’Assignies 2009 | MRI, 1H-MRS | P | 20 (15/5) | 14 NAFLD; 6 ALD | ≤60 days |
Friedrich-Rust 2009 (Epub) | 1H-MRS | P | 45 (1/44) | PBC | Median 21 days; range 0–6 months |
Kim DY 2009 (Epub) | CT | P | 179 (115/64) | Potential living liver donors | 0 days |
Krssak 2009 (Epub) | 1H-MRS | P | 29 (16/13) | HCV | 0 days |
McPherson 2009 | MRI, 1H-MRS | P | 94 (66/28) | 37 HCV; 23 fatty liver; 11 HBV; 7 AIH/PBC; 6 colorectal metastases; 10 other | Median 9 days (range 0–209 days) |
Mennesson 2009 | MRI | P | 40 (20/20) | 10 NAFLD; 9 ALD; 4 AIH; 4 cryptogenic liver disease; 6 other | 0 days |
O’Rourke 2009 | MRI | P | 37 (23/14) | colorectal liver metastases | Unclear |
Tobari 2009 | US, CT | R | 118 (52/66) | NASH | ≤6 months |
Webb 2009 | US | R | 111 (60/51) | 43 NAFLD; 56 HCV; 3 HBV; 9 other | 0 days |
Yamashiki 2009 | US, CT | P | 78 (63/15) | Potential living liver donors | Unclear |
Yu 2009 | US | P | 180 (102/78) | 171 fatty liver; 8 NASH; 1 cirrhosis | Unclear |
Data extraction
Group 1: >0%, >2%, >5% steatosis as positives on biopsy
b
| |||||
p-value
| |||||
n
a
|
Sensitivity (95% CI)
|
US
|
CT
|
MRI
| |
US | 19 | 73.3 (62.2–82.1) | – | – | – |
CT | 6 | 46.1 (22.2–71.8) | NS | – | – |
MRI | 5 | 82.0 (63.7–92.2) | NS | 0.02 | – |
1H-MRS | 3 | 88.5 (76.6–94.7) | 0.04 | <0.01 | NS |
n
a
|
Specificity (95% CI)
|
US
|
CT
|
MRI
| |
US | 19 | 84.4 (76.2–90.1) | – | – | – |
CT | 6 | 93.5 (86.2–97.7) | NS | – | – |
MRI | 5 | 89.9 (81.0–94.9) | NS | NS | – |
1H-MRS | 3 | 92.0 (80.5–97.0) | NS | NS | NS |
n
a
|
ln DOR (95% CI)
|
US
|
CT
|
MRI
| |
US | 19 | 2.70 (1.97–3.43) | – | – | – |
CT | 6 | 2.50 (1.13–3.87) | NS | – | – |
MRI | 5 | 3.70 (2.50–4.90) | NS | NS | – |
1H-MRS | 3 | 4.48 (3.15–5.81) | 0.02 | 0.04 | NS |
Group 2: >10%, >15%, >20% steatosis as positives on biopsy
c
| |||||
p-value
| |||||
n
a
|
Sensitivity (95% CI)
|
US
|
CT
|
MRI
| |
US | 5 | 90.5 (79.3–96.0) | – | – | – |
CT | 8 | 57.0 (51.5–62.3) | <0.01 | – | – |
MRI | 2 | 90.0 (73.2–96.7) | NS | <0.01 | – |
1H-MRS | 2 | 82.6 (61.8–93.3) | NS | 0.02 | NS |
n
a
|
Specificity (95% CI)
|
US
|
CT
|
MRI
| |
US | 5 | 69.6 (60.0–77.7) | – | – | – |
CT | 8 | 88.1 (81.1–92.7) | <0.01 | – | – |
MRI | 2 | 95.3 (83.2–98.8) | <0.01 | NS | – |
1H-MRS | 2 | 94.3 (79.8–98.6) | 0.01 | NS | NS |
n
a
|
ln DOR (95% CI)
|
US
|
CT
|
MRI
| |
US | 5 | 3.09 (2.08–4.09) | – | – | – |
CT | 8 | 2.28 (1.70–2.87) | NS | – | – |
MRI | 2 | 5.22 (3.36–7.07) | 0.05 | <0.01 | – |
1H-MRS | 2 | 4.36 (2.57–6.15) | NS | 0.03 | NS |
Group 3: >25%, >30%, >33% steatosis as positives on biopsy
d
| |||||
p-value
| |||||
n
a
|
Sensitivity (95% CI)
|
US
|
CT
|
MRI
| |
US | 19 | 85.7 (78.4–90.8) | – | – | – |
CT | 15 | 72.0 (59.7–81.7) | 0.03 | – | – |
MRI | 3 | 97.4 (83.5–99.6) | NS | 0.01 | – |
1H-MRS | 2 | 72.7 (41.4–91.0) | NS | NS | 0.03 |
n
a
|
Specificity (95% CI)
|
US
|
CT
|
MRI
| |
US | 19 | 85.2 (76.9–90.9) | – | – | – |
CT | 15 | 94.6 (88.1–97.7) | 0.03 | – | – |
MRI | 3 | 76.1 (49.6–91.2) | NS | 0.02 | – |
1H-MRS | 2 | 95.7 (84.5–98.9) | NS | NS | 0.04 |
n
a
|
ln DOR (95% CI)
|
US
|
CT
|
MRI
| |
US | 19 | 3.54 (2.80–4.29) | – | – | – |
CT | 15 | 3.82 (2.79–4.85) | NS | – | – |
MRI | 3 | 4.77 (2.46–7.08) | NS | NS | – |
1H-MRS | 2 | 4.09 (2.15–6.04) | NS | NS | NS |
Group 4: >50%, >60%, >66% steatosis as positives on biopsy
| |||||
n
a
|
Sensitivity (95% CI)
| ||||
US | 9 | 91.1 (63.0–98.4) | |||
CT | 0 | – | |||
MRI | 0 | – | |||
1H-MRS | 0 | – | |||
n
a
|
Specificity (95% CI)
| ||||
US | 9 | 91.9 (74.3–97.8) | |||
CT | 0 |
–
| |||
MRI | 0 | – | |||
1H-MRS | 0 | – | |||
n
a
|
ln DOR (95% CI)
| ||||
US | 9 | 4.75 (3.41–6.08) | |||
CT | 0 | – | |||
MRI | 0 | – | |||
1H-MRS | 0 | – |